WALKERS
25.7.2016 09:01:14 CEST | Business Wire | Press release
Leading international law firm Walkers has today announced that AO Hall, a specialist Guernsey-based provider of legal services has joined the Walkers Group and is now operating as Walkers (Guernsey) LLP.
Walkers (Guernsey) LLP provides an integrated range of services to clients in jurisdictions around the world, covering the following key practice areas: finance, corporate, investment funds, dispute resolution, insolvency & restructuring, employment, pensions, trusts and fiduciary.
Ingrid Pierce, Walkers' global managing partner commented, "The decision to expand our reach into Guernsey was driven in the same way all of our international opening decisions are made, based on the needs of our clients. We have for some time had clients, particularly in Europe, asking us for Guernsey legal services and the opportunities presented in Guernsey make it the logical next step to providing seamless offshore legal services to clients across this region."
Walkers (Guernsey) LLP will continue to be managed by Louise Hall the managing partner at AO Hall and the entire AO Hall team will remain in place, providing existing clients with a seamless transition.
Louise Hall commented: "Becoming part of Walkers offers us and our clients the opportunity to reach a global market and we are delighted that a firm of the calibre and international reputation that Walkers enjoys has chosen Guernsey for its continued global growth. This clearly demonstrates Walkers' confidence in Guernsey as an important offshore business centre."
Founded in 2005 with a team of just five, AO Hall has grown to over 25 staff and has developed a reputation in Guernsey for the particularly high calibre of its market leading lawyers, a sentiment which is echoed each year by both the leading legal directories and clients alike, with eleven of the firm's fourteen lawyers being ranked by the leading legal directories.
"Walkers has worked with AO Hall in Guernsey for a number of years and we knew that joining operations would provide an ideal cultural fit as well as complementing Walkers' practice driven strategy," Jack Boldarin, Walkers' London managing partner, said. "Opening in Guernsey provides a natural supplement to our other international offices and dovetails with both our existing Channel Islands office in Jersey and our office in London."
About Walkers
Walkers is a pre-eminent International Finance Centre law firm which operates through a network of offices across the globe providing multi-jurisdictional service.
Please visit www.walkersglobal.com for further information about the Walkers Group.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160725005191/en/
Contact:
Walkers
John Partridge, Head of Business Development, UK & Channel
Islands
DD: +44 (0)20 7220 4993
M: +44 (0)7812 222 042
john.partridge@walkersglobal.com
or
Philippa
Bullmore, Head of Marketing Operations
DD: +1 345 814 4596
M:
+1 345 525 8425
philippa.bullmore@walkersglobal.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom